🔬Deep Research
UPB — Upstream Bio Inc · catalysts, narrative & risks
Upstream Bio, Inc. (NASDAQ: UPB) — as of 2026-10-31
Upstream Bio is a clinical-stage biotech headquartered in Waltham, Massachusetts, with a single clinical asset, verekitug, an investigational long-acting monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor. As of the Oct. 30, 2026 close, the stock traded near $3.41 with a market capitalization of roughly $187 million, down about 87% year-to-date and roughly 90% from its January 2026 52-week high of $33.68 [2], [11], [16], [17].
Recent Catalysts (approx. July–October 2026)
AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →